Patent: 5,549,892
✉ Email this page to a colleague
Summary for Patent: 5,549,892
Title: | Enhanced in vivo uptake of glucocerebrosidase |
Abstract: | A pharmaceutical composition comprising remodelled recombinant glucocerebrosidase (GCR) is described that provides a therapeutic effect at doses that are lower then those required using remodelled naturally occurring GCR. A method of treating patients with Gaucher\'s disease using remodelled recombinant GCR is also provided. In vivo uptake of exogenous molecules can be determined by extracting a mixture of cells from a subject, enriching the target cells in vitro, lysing the cells and determining the amount of exogenous molecules. |
Inventor(s): | Friedman; BethAnn (Arlington, MA), Hayes; Michael (Acton, MA) |
Assignee: | Genzyme Corporation (Cambridge, MA) |
Application Number: | 08/080,855 |
Patent Claims: | see list of patent claims |
Details for Patent 5,549,892
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genzyme Corporation | CEREZYME | imiglucerase | For Injection | 020367 | May 23, 1994 | ⤷ Sign Up | 2013-08-27 |
Genzyme Corporation | CEREZYME | imiglucerase | For Injection | 020367 | September 22, 1999 | ⤷ Sign Up | 2013-08-27 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 5,549,892
Country | Patent Number | Estimated Expiration |
---|---|---|
World Intellectual Property Organization (WIPO) | 9007573 | ⤷ Sign Up |
United States of America | 6451600 | ⤷ Sign Up |
United States of America | 5236838 | ⤷ Sign Up |
United States of America | 2005026249 | ⤷ Sign Up |
United States of America | 2005019861 | ⤷ Sign Up |
United States of America | 2002168750 | ⤷ Sign Up |
Japan | H03503721 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |